Phase II study to evaluate the efficacy and safety of Herceptin in combination with XELOX as first-line treatment for advanced or metastatic gastric cancer patients with HER2-positive tumors.

Trial Profile

Phase II study to evaluate the efficacy and safety of Herceptin in combination with XELOX as first-line treatment for advanced or metastatic gastric cancer patients with HER2-positive tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HerXO
  • Most Recent Events

    • 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Planned End Date changed from 6 Jul 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top